Modality
mAb
MOA
STINGag
Target
IL-23
Pathway
Hedgehog
IgANET
Development Pipeline
Preclinical
~Oct 2013
→ ~Jan 2015
Phase 1
~Apr 2015
→ ~Jul 2016
Phase 2
~Oct 2016
→ ~Jan 2018
Phase 3
Apr 2018
→ Nov 2031
Phase 3Current
NCT06095932
1,670 pts·IgAN
2018-04→2029-12·Recruiting
NCT06433100
1,060 pts·ET
2019-06→2031-11·Terminated
NCT04579720
2,204 pts·IgAN
2021-08→2030-09·Completed
4,934 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2029-12-143.7y awayPh3 Readout· IgAN
2030-09-054.4y awayPh3 Readout· IgAN
2031-11-145.6y awayPh3 Readout· ET
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Recruit…
P3
Termina…
P3
Complet…
Catalysts
Ph3 Readout
2029-12-14 · 3.7y away
IgAN
Ph3 Readout
2030-09-05 · 4.4y away
IgAN
Ph3 Readout
2031-11-14 · 5.6y away
ET
RecruitingCompletedTerminated|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06095932 | Phase 3 | IgAN | Recruiting | 1670 | PANSS |
| NCT06433100 | Phase 3 | ET | Terminated | 1060 | ACR20 |
| NCT04579720 | Phase 3 | IgAN | Completed | 2204 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| Tezecilimab | Regeneron | Approved | IL-23 |